Status:
COMPLETED
Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19
Lead Sponsor:
Eurnekian Public Hospital
Conditions:
Severe Acute Respiratory Syndrome
Ventilation Pneumonitis
Eligibility:
All Genders
5+ years
Brief Summary
The associated use of Ivermectin, aspirin, dexamethasone, and enoxaparin (in different combinations and doses) will reduce the impact of COVID infection 19, the need of admission to the intensive care...
Detailed Description
Between 30 and 50% of patients who contract COVID 19 will be asymptomatic or oligosymptomatic. This fact will not give rise to the consult, and will directly affect a notorious sub-registration of the...
Eligibility Criteria
Inclusion
- patients with positive oral/nasal swabs
Exclusion
- Children under 5 years old Pregnant women Previous reports of allergy to any of the drugs used in the clinical trial
Key Trial Info
Start Date :
May 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 30 2020
Estimated Enrollment :
167 Patients enrolled
Trial Details
Trial ID
NCT04425863
Start Date
May 1 2020
End Date
August 30 2020
Last Update
October 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Eurnekian
Buenos Aires, Argentina, 1802